Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 10/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | CCKBR | P32239 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2764206 | 0.89 | L3MBTL1 (0.53) | L3MBTL1MAPTPOLBTP53CCKBR | |
| Hydrochloric Acid SCHEMBL2766753 | 0.88 | L3MBTL1 (0.52) | L3MBTL1MAPTPOLBTP53CCKBR | |
| SCHEMBL14569197 | 0.87 | L3MBTL1 (0.67) | L3MBTL1MAPTPOLBTP53CCKBR | |
| SCHEMBL788538 | 0.86 | L3MBTL1 (0.65) | L3MBTL1MAPTPOLBTP53CCKBR | |
| SCHEMBL15882461 | 0.85 | L3MBTL1 (0.61) | L3MBTL1MAPTPOLBTP53CCKBR | |
| SCHEMBL14393003 | 0.82 | L3MBTL1 (0.61) | L3MBTL1MAPTPOLBTP53CCKBR | |
| SCHEMBL14026306 | 0.79 | L3MBTL1 (0.57) | L3MBTL1MAPTPOLBTP53CCKBR | |
| SCHEMBL3401284 | 0.77 | MAPT (0.44) | L3MBTL1MAPTPOLBTP53NPC1 | |
| SCHEMBL5485930 | 0.76 | L3MBTL1 (0.54) | L3MBTL1MAPTPOLBTP53CCKBR | |
| SCHEMBL12334080 | 0.76 | MAPT (0.51) | L3MBTL1MAPTPOLBTP53CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252590-A1 | SUBSTITUTED SULFONIC ACID AMIDE COMPOUNDS | BASF SE (DE) | 2010-11-24 | — | — | EP | claimed |
| EP-1694410-B1 | CYCLOPROPANE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2010-04-14 | — | — | EP | claimed |
| WO-2009101082-A1 | SUBSTITUTED SULFONIC ACID AMIDE COMPOUNDS | BASF SE (DE) | 2009-08-20 | — | — | WO | claimed |
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. | 2008-10-23 | — | — | US | claimed |
| WO-2008124524-A2 | ARYL SULFONAMIDE COMPOUNDS AS MODULATORS OF THE CCK2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-16 | — | — | WO | claimed |
| US-7351825-B2 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2008-04-01 | — | — | US | claimed |
| US-20060199826-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2006-09-07 | — | — | US | claimed |
| US-20040198979-A1 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-10-07 | — | — | US | claimed |
| EP-1387679-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2004-08-11 | — | — | EP | claimed |
| EP-1387679-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-11 | — | — | EP | claimed |
| WO-2002089793-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | claimed |
| WO-2010146236-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORP. (FI) | 2010-12-23 | — | — | WO | disclosed |
| EP-2252590-A1 | SUBSTITUTED SULFONIC ACID AMIDE COMPOUNDS | BASF SE (DE) | 2010-11-24 | — | — | EP | disclosed |
| US-20100105894-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. | 2010-04-29 | — | — | US | disclosed |
| EP-1694410-B1 | CYCLOPROPANE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-20060199826-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2006-09-07 | — | — | US | disclosed |
| US-20040198979-A1 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-10-07 | — | — | US | disclosed |
| EP-1387679-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2004-08-11 | — | — | EP | disclosed |
| EP-1387679-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002089793-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199826-A1 | Cyclopropane compounds and pharmaceutical use thereof | MMP13, MMP9, MMP11 | L3MBTL1 4360/4885MAPT 3895/4885POLB 3144/4885 |
| US-20040198979-A1 | Sulfonamides | UTS2R, PRSS2, STS | L3MBTL1 4850/4885MAPT 2260/4885POLB 4372/4885 |
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | MMP13, MMP9, MMP11 | L3MBTL1 4378/4885MAPT 3899/4885POLB 3179/4885 |
| US-20100105894-A1 | Cyclopropane compounds and pharmaceutical use thereof | MMP13, MMP9, MMP11 | L3MBTL1 4378/4885MAPT 3899/4885POLB 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.